Olema Pharmaceuticals gets buy rating from Guggenheim with $35 target
OLMA•Guggenheim assumed coverage of Olema Pharmaceuticals with a buy rating and a $35 target price.
Related News
Dr. Reddy's wins Brazil approval for generic semaglutide injection
RDY•
Vishay Intertechnology target price cut to $35 from $40
VSH•
Piper Sandler cuts HubSpot target price to $200 from $220
HUBS•
JPMorgan cuts HubSpot target price to $224 from $240
HUBS•
Edwards Lifesciences target price raised to $120 from $105 by JP Morgan
EW•